Wordt geladen...
Application of CRISPR/Cas9 Technology to HBV
More than 240 million people around the world are chronically infected with hepatitis B virus (HBV). Nucleos(t)ide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (c...
Bewaard in:
| Hoofdauteurs: | , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
MDPI AG
2015-11-01
|
| Reeks: | International Journal of Molecular Sciences |
| Onderwerpen: | |
| Online toegang: | http://www.mdpi.com/1422-0067/16/11/25950 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|